Ignite Creation Date:
2025-12-25 @ 4:40 AM
Ignite Modification Date:
2026-03-12 @ 6:09 AM
Study NCT ID:
NCT03651518
Status:
RECRUITING
Last Update Posted:
2025-11-20
First Post:
2018-06-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Personalized Therapies in Inflammatory Complex Disease
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Study Overview
Official Title:
Personalized Targeted Therapies in Inflammatory Complex Multi Organ Disease
Status:
RECRUITING
Status Verified Date:
2025-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PIMOC
Brief Summary:
Inflammatory diseases may display atypical features making such patients impossible to classify. Management of these cases in daily practice cannot rely on the results of clinical trials nor on guidelines. DNA and RNA mapping have become major tools to understand and sometimes direct the treatment strategy in oncology. This study aims to test whether a precise analysis of molecular pathways in inflammatory, non classified diseases, can constitute a predictive tool of therapeutic efficiency
Detailed Description:
This is a phase IIb study. The main objective of this study is to evaluate the efficacy of targeted treatments in patients displaying a non-classified, severe and resistant inflammatory disease. Targeted treatments for each patient will have been selected through an algorithm based on molecular analysis of specific altered inflammatory signaling pathway.
Treatments consist in targeted therapies approved in other indications (Kineret®, Humira®, Stelara®, Cosentyx®, Roactemra® and Rituximab®) that will be given once selected using molecular analysis and decision making procedure by the Scientific committee.
For each patient, one targeted treatment will be administered according to the SmPC procedure for a treatment period of 6 months.
Primary efficacy endpoint:
Response will be assessed at month 6 with a composite endpoint defined as improvement of at least 2 of the 3 following parameters:
* 50% improvement of the systemic activity assessed by the clinician following a visual analog scale (0-10 mm),
* and/or 50% improvement of cutaneous activity assessed by the involved skin surface area,
* and/or 50% decrease or normalisation of biological markers of inflammation (either CRP, ESR or fibrin).
An independent adjudication committee blinded to the treatment received, will review primary endpoint for all patients based on clinical files and standardized photographs, to validate the response.
Other secondary criteria will be assessed. Overall, this study will require a molecular analysis done on patient's tissue, the final aim being to evaluate efficiency and tolerance of targeted treatments chosen in a personalized analysis when classification is impossible.
Treatments consist in targeted therapies approved in other indications (Kineret®, Humira®, Stelara®, Cosentyx®, Roactemra® and Rituximab®) that will be given once selected using molecular analysis and decision making procedure by the Scientific committee.
For each patient, one targeted treatment will be administered according to the SmPC procedure for a treatment period of 6 months.
Primary efficacy endpoint:
Response will be assessed at month 6 with a composite endpoint defined as improvement of at least 2 of the 3 following parameters:
* 50% improvement of the systemic activity assessed by the clinician following a visual analog scale (0-10 mm),
* and/or 50% improvement of cutaneous activity assessed by the involved skin surface area,
* and/or 50% decrease or normalisation of biological markers of inflammation (either CRP, ESR or fibrin).
An independent adjudication committee blinded to the treatment received, will review primary endpoint for all patients based on clinical files and standardized photographs, to validate the response.
Other secondary criteria will be assessed. Overall, this study will require a molecular analysis done on patient's tissue, the final aim being to evaluate efficiency and tolerance of targeted treatments chosen in a personalized analysis when classification is impossible.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2017-000519-18 | REGISTRY | ID-RCB | View |